Open Access Articles- Top Results for BMY-14802


Systematic (IUPAC) name
Clinical data
105565-55-7 7pxY
PubChem CID 108046
ChemSpider 97151 7pxN
Chemical data
Formula C18H22F2N4O
348.389 g/mol
 14pxN (what is this?)  (verify)

BMY-14802 is a drug with antipsychotic effects, which acts as both a sigma receptor antagonist, and a 5-HT1A agonist.[1][2][3][4]


  1. ^ Taylor DP, Eison MS, Moon SL, Schlemmer RF, Shukla UA, VanderMaelen CP, Yocca FD, Gallant DJ, Behling SH, Boissard CG (1993). "A role for sigma binding in the antipsychotic profile of BMY 14802?". NIDA Research Monograph 133: 125–57. PMID 8232511. 
  2. ^ Vanecek SA, Essman WD, Taylor DP, Woods JH (January 1998). "Discriminative stimulus characteristics of BMY 14802 in the pigeon". The Journal of Pharmacology and Experimental Therapeutics 284 (1): 1–9. PMID 9435153. 
  3. ^ Kitanaka J, Kitanaka N, Tatsuta T, Hall FS, Uhl GR, Tanaka K, Nishiyama N, Morita Y, Takemura M (May 2009). "Sigma1 receptor antagonists determine the behavioral pattern of the methamphetamine-induced stereotypy in mice". Psychopharmacology 203 (4): 781–92. PMC 3157915. PMID 19052726. doi:10.1007/s00213-008-1425-z. 
  4. ^ Paquette MA, Foley K, Brudney EG, Meshul CK, Johnson SW, Berger SP (July 2009). "The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism". Psychopharmacology 204 (4): 743–54. PMC 2845289. PMID 19283364. doi:10.1007/s00213-009-1505-8. 

Lua error in package.lua at line 80: module 'Module:Buffer' not found.